Mechanisms of Muscle Weakness Associated with Bone Metastases
暂无分享,去创建一个
[1] A. Molfino,et al. Perioperative nutritional intervention: a way to improve long-term outcomes , 2016, Nature Reviews Clinical Oncology.
[2] R. Lovering,et al. Critical Role of Intracellular RyR1 Calcium Release Channels in Skeletal Muscle Function and Disease , 2016, Front. Physiol..
[3] Wenjun Xie,et al. Excess TGF-β mediates muscle weakness associated with bone metastases in mice , 2015, Nature Medicine.
[4] S. Anker,et al. Prevalence, incidence and clinical impact of cachexia: facts and numbers—update 2014 , 2014, Journal of cachexia, sarcopenia and muscle.
[5] J. Frank,et al. Structure of a mammalian ryanodine receptor , 2014, Nature.
[6] G. Ávila,et al. Ryanodine receptors as leak channels. , 2014, European journal of pharmacology.
[7] Arash Salmaninejad,et al. Roles of oxidative stress in the development and progression of breast cancer. , 2014, Asian Pacific journal of cancer prevention : APJCP.
[8] F. Sotgia,et al. Tumor microenvironment and metabolic synergy in breast cancers: critical importance of mitochondrial fuels and function. , 2014, Seminars in oncology.
[9] V. Baracos,et al. Understanding the mechanisms and treatment options in cancer cachexia , 2013, Nature Reviews Clinical Oncology.
[10] T. Moliné,et al. Oxidative stress and cancer: An overview , 2013, Ageing Research Reviews.
[11] J. Bartek,et al. IL1- and TGFβ-Nox4 signaling, oxidative stress and DNA damage response are shared features of replicative, oncogene-induced, and drug-induced paracrine ‘Bystander senescence’ , 2012, Aging.
[12] D. Glass,et al. Cancer cachexia: mediators, signaling, and metabolic pathways. , 2012, Cell metabolism.
[13] Raynoo Thanan,et al. Role of Nitrative and Oxidative DNA Damage in Inflammation-Related Carcinogenesis , 2012, Journal of biomedicine & biotechnology.
[14] J. Stamler,et al. Oxygen-coupled redox regulation of the skeletal muscle ryanodine receptor-Ca2+ release channel by NADPH oxidase 4 , 2011, Proceedings of the National Academy of Sciences.
[15] T. Shiomi,et al. Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. , 2011, Cell metabolism.
[16] Michael D. Schneider,et al. NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart , 2010, Proceedings of the National Academy of Sciences.
[17] A. Verkhratsky,et al. An intelligent sarco-endoplasmic reticulum Ca2+ store: release and leak channels have differential access to a concealed Ca2+ pool. , 2010, Cell calcium.
[18] A. Marks,et al. Fixing ryanodine receptor Ca leak - a novel therapeutic strategy for contractile failure in heart and skeletal muscle. , 2010, Drug discovery today. Disease mechanisms.
[19] S. Matecki,et al. Hypernitrosylated ryanodine receptor/calcium release channels are leaky in dystrophic muscle , 2009, Nature Medicine.
[20] S. Reiken,et al. Remodeling of ryanodine receptor complex causes “leaky” channels: A molecular mechanism for decreased exercise capacity , 2008, Proceedings of the National Academy of Sciences.
[21] A. Saxena,et al. Antioxidant status in advanced cervical cancer patients undergoing neoadjuvant chemoradiation , 2007, British journal of biomedical science.
[22] P. Delmas,et al. Bone quality--the material and structural basis of bone strength and fragility. , 2006, The New England journal of medicine.
[23] S. Reiken,et al. Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[24] G. Peluso,et al. Skeletal muscle metabolism in physiology and in cancer disease , 2003, Journal of cellular biochemistry.
[25] C. Cordon-Cardo,et al. A multigenic program mediating breast cancer metastasis to bone. , 2003, Cancer cell.
[26] R Wieser,et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. , 1999, The Journal of clinical investigation.
[27] R. Coleman. Skeletal complications of malignancy , 1997, Cancer.
[28] J. Yingling,et al. Development of TGF-beta signalling inhibitors for cancer therapy. , 2004, Nature reviews. Drug discovery.